Ebtisam Alumin Osman, MD
Neurology · Atlanta, GANPI 1659759207
Payments from drug & device makers
Across 106 payments — averaging $42.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Jazz Pharmaceuticals Inc.$591
- UCB, Inc.$523
- AbbVie$403
- Argenx US, Inc.$145
- Pfizer$125
- plus $926 from 20 others
What the payments were for
- Travel & lodging$1,10225%
- Food & beverage$3,38275%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 7 | $1,771 |
| Jazz Pharmaceuticals Inc. | 7 | $591 |
| UCB, Inc. | 14 | $523 |
| AbbVie | 22 | $403 |
| Argenx US, Inc. | 6 | $145 |
| Pfizer | 5 | $125 |
| Amgen | 6 | $121 |
| AstraZeneca | 7 | $120 |
| Upsher-smith Laboratories LLC | 5 | $87 |
| Eisai Inc. | 4 | $74 |
| Impel Pharmaceuticals Inc. | 3 | $62 |
| SK Life Science, Inc. | 2 | $59 |
| Neurocrine Biosciences, Inc. | 2 | $58 |
| Lundbeck LLC | 2 | $44 |
| Neuropace, Inc. | 1 | $41 |
| Biogen | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Neurelis, Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Sanofi | 1 | $25 |
| EMD Serono, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,606
- Epidiolex$397
- Fintepla$349
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$100
How this compares
$4,484 in reported general payments places this provider in the 60th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 30 | $269,925 |
| IngrezzaValbenazine Tosylate | 11 | $89,103 |
| Nurtec OdtRimegepant Sulfate | 37 | $50,965 |
| QuliptaAtogepant | 24 | $38,234 |
| Lamictal XrLamotrigine | 11 | $37,066 |
| UbrelvyUbrogepant | 20 | $26,845 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $21,978 |
| Lacosamide | 133 | $15,423 |
| Emgality PenGalcanezumab-Gnlm | 20 | $14,929 |
| Depakote ErDivalproex Sodium | 17 | $12,272 |
| Levetiracetam | 181 | $7,165 |
| Memantine Hcl | 169 | $5,205 |
| Felbamate | 12 | $3,646 |
| Gabapentin | 166 | $3,400 |
| Donepezil Hcl | 219 | $2,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $58 | $89,10311 claims |
| AbbVieQulipta, Ubrelvy | $403 | $65,07944 claims |
| PfizerNurtec Odt | $125 | $50,96537 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $16 | $84213 claims |
| Upsher-smith Laboratories LLCTopiramate | $87 | $54944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 506 neurology providers in Georgia.
Other neurology in Atlanta
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
- Julio FlaminiAtlanta$1.6M
- Joash LazarusAtlanta$1.4M
- Frank BerensonAtlanta$1.2M
- Stewart FactorAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.